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The  recovery of  an  animal from  a  primary viral infection has  been  extensively 
studied, but the relative importance of the several immune factors in this process has 
not been established. In recent years increased emphasis has been placed on the im- 
portance of cellular immunity and the relative lack of importance of humoral antibody 
in this recovery process (1,  2). This impression is partially based on the observation 
that patients thought to have primarily defects in cellular immunity are much more 
susceptible to certain viral infections, particularly vaccinia virus infections (2,  3). In 
addition it has recently been shown  that administration of anti-thymocyte Or anti- 
lymphocyte  sera  will  significantly increase  the  mortality  of  mice  infected  with  a 
number  of viruses, including vaccinia vilus  (4-7). 
A series of investigations was designed to study the role of cellular immunity, 
humoral antibody, and interferon in recovery from primary systemic vaccinia 
virus  infection  in  mice.  Vaccinia virus  was  chosen  because  it  appears  to  be 
generally regarded as a viral infection in which there is a critical role for cellular 
immunity  in  the  recovery process,  both in  man  and  in  experimental  animals 
(3, 5). It was planned to eventually use a  number of different immunosuppres- 
sive agents, in the hope that different deletions of the components of the immune 
system would result in patterns of enhanced infection in proportion to the im- 
portance  of the immune  factors.  In the first of the  studies  experiments were 
performed using cyclophosphamide (Cytoxan) as an immunosuppressive agent; 
the results suggest an essential role for humoral antibody, but not for cellular 
immunity, in recovery from primary vaccinia virus infection in the mouse. 
Materials and Methods 
Animals.--6-wk old NIH Swiss male mice and 6-wk old C57/BL6 male mice were obtained 
from the National Institutes of Health colonies. 
Vacclnia  Virus Strain.--Neurovaccinia virus was obtained from Dr. W. A. Casel, Emory 
University, Atlanta. Vaccinia  virus was  grown  on  the chick embryo chorioallantoic mem- 
brane; the pool titered 107.0 l.n~0/0.05 ml when inoculated intracutaneously (i.c.) into wean- 
ling Swiss male mice and 106 plaque-forming units (PFU) 1/ml on vero cells. 
1Abbreviations  used in  this  paper:  ATS,  anti-thymocyte serum;  EMC,  encephalomyo- 
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Vaccinia  Virus  Assay.- Individual  mice were  bled  by  the  orbital  technique, and  serial 
10-fold  dilutions  of  each  serum in  Eagle's  medium with  2%  fetal  calf  serum  (FCS)  were 
assayed for vaccinia virus content by plaque titration on vero cells. 
Neutralizing Antibody  Tests.--Individual  mouse sera were assayed for anti-vaccinia virus 
antibody by a  plaque reduction method. Samples of vaccinia virus containing 50 PFU/0.2 cc 
were incubated with 3-fold dilutions of serum in Eagle's medium with 2%  FCS at 37°C for 
2 hr; each mixture was then plaque assayed on veto cells. A control sample of vaccinia virus 
incubated with normal mouse serum was included in each experiment. 
Lymphocytic  Choriomeningitis  Virus.--Lymphocytic  choriomeningitis  virus  (LCM) 
strain  CA1371  was obtained from Dr.  W.  Rowe  of the NIH.  It  had  been grown in mouse 
brains; a  10%  w/v  suspension was made just  before  use, using Eagle's medium with  10% 
FCS. Further dilutions were also made in Eagle's medium with 10% FCS. 
Interferon Ass~tys.--At  various time intervals after injection of virus, five mice from each 
group were bled and their blood pooled. The blood was centrifuged at  1500 rpm for 20 rain 
and the serum was then stored at --20°C in a  mechanical freezer. The serum interferon titers 
were  determined  as the  reciprocal  of the highest dilution  of serum which inhibited  the he- 
magglutinin yield of GD-7  virus during a  single growth cycle in mouse L  cells  by 0.5 logl0. 
Titers were adjusted in accordance with the titer of a  laboratory reference interferon which 
was titered  in each assay. The international reference mouse serum interferon  titered  104.5 
units/ml. 
llyperimmune Anti-Vaccinia  Virus  Ant{body.--2-kg  female rabbits  were  injected  subcu- 
taneously  (s.c.)  with  10 ~ PFU of vaccinia virus, and 2  wk later  they received  a  similar s.c. 
injection.  I  wk after this they received a  third s.c. injection of virus, and a  week later they 
were bled by intracardiac puncture. The blood was allowed to clot overnight at 0°C and sera 
were then separated by centrifugation at 1500 rpm for 25 min. 
Immune Lymphocytes.---The  method described  by Fred  and  Smith was  used to  prepare 
immune lymphocytes (8). 2 wk after intravenous (i.v.) injection of 104 PFU of vaccinia virus, 
mice were sacrificed and their spleens collected.  At this time the mice were immune as indi- 
cated  by  serum  anti-vaccinia  antibody  titers  of  about  1:1000.  Mice  immunized  to  LCM 
virus received three weekly intraperitoneal  (i.p.) injections of 10  a i.e. LDS0 of this virus. Their 
spleens were collected 1 wk after the third i.p. injection. Suspensions of individual spleen cells 
~ere prepared  and the viability of the cells was determined by trypan blue exclusion. Each 
recipient  mouse was injected slowly i.v. with l0  s viable cells in 0.5 cc of phosphate-buffered 
saline (PBS)  on the day indicated. Some control mice received just 0.5 cc of PBS while others 
received no injection. 
Cyclophosphamide.--Cyclophosphamide  (Cytoxan) was obtained from Mead Johnson and 
Co., Evansville, Ind., and a solution in phosphate-buffered saline with a final concentration of 
20 mg/ml was prepared just before use. 
Experimental Design 
All mice were injected i.v. with 104 PFU of vaccinia virus in 0.I cc of Eagle's medium with 
2% fetal calf serum on day 0.24 hr later one group of mice was injected i.p. with 150 mg/kg 
body weight of Cytoxan in 0.3  cc of PBS.  A  control group of mice received  only 0.3  cc of 
PBS i.p. Each day after injection of virus three mice from each group were bled individually 
by the orbital  method and the titer of viremia determined; three other mice from each group 
were also bled and the titer of serum anti-vaccinia antibody determined. The sera from five 
mice from both Cytoxan-treated and control groups were pooled within groups each day and 
assayed for interferon.  After these initial studies replacement with vaccinia immune sera or 
immune lymphocytes was performed on different days after injection of virus. All mice were 
held for at least 28 days before an experiment was terminated. 
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RESULTS 
Effect of Cytoxan on Mortality from Primary Vaccinia  Virus Infection.--The 
results presented in Fig.  1 demonstrate that Cytoxan treatment markedly in- 
creased the mortality of vaccinia virus-infected Swiss male mice. Mice which 
received just vaccinia virus had 10 % mortality, while Cytoxan-treated mice had 
94 % mortality. Cytoxan treatment alone did not kill any mice. 
Effect of Cytoxan on Viremia.--The results presented  in  Fig. 2  demonstrate 
that  viremia in  Cytoxan-treated  Swiss  mice  paralleled  that  of nonimmuno- 
suppressed control mice for the 1st 3 days after infection. However, viremia in 
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F16.  1.  Effect of Cytoxan on vaccinia virus infection in Swiss mice. 
Cytoxan-treated mice did not decline on the 4th day after infection, but rather 
continued to rise and remained high until the death of the mice on the 7th or 
8th day after infection. These results suggest that Cytoxan interfered with some 
host defense mechanism(s) which became effective on about the 4th day after 
infection and resulted in a termination of viremia. 
Effect of Cytoxan on Serum Interferon  Levels.--Mice  injected  with vaccinia 
virus had serum interferon level of 80 units/ml 8 hr after virus infection, but no 
interferon was detected in the sera of either Cytoxan-treated or control mice on 
any day after this. Interferon levels in organs were not studied. 
Effect of Cytoxan  on Serum-Neutralizing  Antibody.--Cytoxan-treated  mice 
formed no neutralizing  antibody  to vaccinia virus  (with  a  single  exception), 
while all control Swiss mice studied had significant levels of antibody by the 4th 
day after infection  (Fig. 3). Identical results were obtained in C57/BL6 mice 
except that only one of three control mice had antibody on day 4; three of three 
had antibody on day 5 after infection and on each subsequent day. Cytoxan- 280  RECOVERY  FROM  SYSTEMIC  VACCLNIA  VIRUS  INFECTION 
treated mice again did not form any detectable neutralizing antibody. These 
results suggest that suppression of neutralizing antibody formation might be the 
mechanism by which Cytoxan potentiated vaccinia virus infection. To test this 
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Fro. 2.  Effect of Cytoxan on viremia in vaccinia virus infection in Swiss mice. 
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FIG.  3.  Effect of Cytoxan on formation of neutralizing antibody to vaccinia virus. 
possibility vaccinia-neutralizing antibody was  administered passively to Cy- 
toxan-treated mice at various times after vaccinia infection. 
Effect of Passive Antibody Administration in Cytoxan-Treated,  Vaccinia  Virus- 
I@cted Mice.--Before using passively transferred antibody it was necessary to 
demonstrate that the levels of serum antibody obtained by the transfer were 
physiologic. Four  C57/BL6 mice were injected i.p.  with 0.4 cc of undiluted M.  WORTttINGTON,  A.  S.  RABSON~  AND  S.  BARON  281 
vaccinia immune sera and bled at various time intervals. 6 hr and 3 days after 
injection  of  vaccinia immune  sera  these  mice  had  serum  antibody  titers  of 
between 30 and 70. This is similar to the serum antibody titers of nonimmuno- 
suppressed mice 4 or 5 days after primary infection (Fig. 3). 
Table I summarizes four experiments using C57/BL6 mice in which antibody 
was passively transferred on various days after virus infection. In each experi- 
ment there were 40 mice in the group receiving just vaccinia virus and Cytoxan, 
and 20 mice in each of the other groups. The results of these four experiments 
are combined in Fig. 4, which shows the time-course of mortality in the different 
groups.  It is apparent  that passive administration of physiologic amounts  of 
TABLE I 
Effect ~  Antibody Replacementon Vaccinia Viruslnfectionin  Cytoxan-Treated Mice 
% Mortality 
Antibody administered  Only  Vaccinia 
No. of  vaccinia  Only  virus 
exp.  virus  Cytoxan  Cytoxan 
control  Day 3 *  Day 4*  Day 5*  Day 6*  Day 7* 
1  8~  5  85  20§  20§  20§  --  -- 
2  0  10  100  --  --  30§  40§  65§ 
3  0  0  100  --  --  20§  --  -- 
4  0  0  80  --  --  20§  30§  30§ 
Average  2  4  91  20§  20§  23§  35§  48§ 
* Mice were injected i.v. on day 0 with 104 PFU of vaccinia virus on 0.1  cc of  Eagle's 
medium  with 2% fetal calf serum;  24 hr later they received  150 mg/kg of body weight of 
Cytoxan i.p. A single injection of vaccinia immune serum was administered i.p. on the in- 
dicated day after virus infection. All mice were observed for at least 4 wk. 
:~ %  Mortality. 
§ P  <  0.01. 
-- =  Not done. 
antibody on days 4  and 5, when similar levels of antibody are present in non- 
immunosuppressed controls, largely reversed the enhancement of this infection 
by Cytoxan. Administration of antibody as late as the 7th day after infection 
still reduced final mortality by about 50%. Similar results were obtained when 
Swiss mice were used  instead of  C57/BL6  mice.  These  results thus  strongly 
suggest that formation of neutralizing antibody is a critical host defense mecha- 
nism in this infection. 
Effect of Cytoxan on Cellular Immunity.--Because  of the unavailability of a 
reliable test for cellular immunity to vaccinia virus in mice, it was not possible to 
determine the effect of Cytoxan on this parameter of host defense. A single dose 
of Cytoxan has been  reported to protect mice against acute disease after i.c. 
injection with LCM virus (9) ; this acute LCM disease is thought  to be a  cell- 
mediated immunopathological disease (9-11). 282  RECOVERY  FRO?~  SYSTEMIC  VACCINIA  VIRUS  INFECTION 
Fig. 5 shows the protective effect of a single dose of 150 mg/kg of Cytoxan i.p. 
2 or 3 days after i.c. injection of Swiss male mice with 103 i.e. LD:,0  LCM virus in 
0.05 cc. ]'here were 15 mice in the group receiving just LCM virus, and 10 mice 
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FIG.  4.  Effect of  antit)ody (AB) replacement on  vaccinia  virus infection in  Cytoxan- 
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FIG. ,5.  Effect of Cytoxan on acute LCM infection. 
in  each  of  the  Cytoxan-treated  groups.  Similar  results  were  obtained  with 
C57/BL6  male mice. Thus, the dose of Cytoxan used in these experiments sup- 
pressed the cell-mediated immune response of mice to L('M virus. 
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Treated Mice.--Cytoxan  has been shown  to suppress  cellular immunity in  a 
variety of systems (12), and this was confirmed under the present conditions by 
its effect on experimental infection with LCM virus. To determine if correction 
of this defect would influence the outcome of this infection, immune lympho- 
cytes were transferred to Cytoxan-treated C57/BL6 mice. Before this could be 
done, it was necessary to demonstrate that  the transferred immune lympho- 
cytes were capable of manifesting an immune response. Male C57/BL6 mice 
were injected i.c. with 103 LD~0 of LCM virus; 3 days later they received a single 
dose of 150 mg/kg of Cytoxan i.p. As already noted, mice receiving Cytoxan 
were protected against acute LCM disease. 7 days after receiving Cytoxan, one 
group of 15 mice were injected i.v. with  l0  s spleen cells from LCM immune 
mice; another group of 15 mice received just PBS i.v. All 15 mice receiving the 
immune lymphocytes developed acute LCM disease and were dead by 9 days 
after injection of the cells; 14 of the 15 mice injected with PBS were alive and 
appeared well 3  wk after receiving the  PBS.  These  results indicate that  the 
transferred immune spleen cells  were capable of  mounting a  potent immune 
response. 
Effect of Transfer of Immune  Lymphocytes  on  Vaecinia  Virus Injection  in 
Cytoxan-Treated Mice.--In each experiment on various days after vaccinia virus 
infection 15 mice were injected slowly i.v. with 0.5  ml of PBS containing l0  s 
viable spleen cells from vaccinia immune mice. Fig. 6 summarizes three experi- 
ments performed in this manner. Injection of immune lymphocytes on day 3 
after infection gave minimal protection, about the same effect as that of anti- 
body transferred on day 7. Transfer of immune cells later than the 3rd day after 
infection had no significant effect on final mortality (Fig. 6). Four of the sur- 
viving mice injected with immune cells on day 3 after infection were bled on the 
12th day after infection and their sera tested for antibody to vaccinia virus. All 
four sera had neutralizing antibody to vaccinia virus ranging from 102  to llY 
units/0.2  cc.  This finding raises  the  possibility  that  these  cells  might  have 
exerted their antiviral  effect by making neutralizing antibody. These results 
indicate that even large numbers of immune lymphocytes are far less effective at 
reversing the effect of Cytoxan on vaccinia virus infection than passive antibody 
administration. 
Pathology.--On days 3, 5, and 7 after injection of vaccinia virus, three mice 
from each of the experimental groups were sacrificed; the brain, heart, lungs, 
liver, spleen, and kidneys of each mouse were removed, fixed in B-5 solution 
(formal sublimate), sectioned, and stained with hematoxylin and eosin. On day 
3 after infection vaccinia-infected mice, both Cytoxan-treated and control, had 
focal areas of mild interstitial pneumonia and rare areas of focal hepatic necro- 
sis. On day 5 after infection both groups demonstrated areas of focal necrosis 
with some polymorphonuclear cell infiltration in the lungs and tile liver. There 
was  no  definite difference in  the  type or  severity of these histopathological 
lesions in these two experimental groups on either day 3 or day 5 after infection. 284  RECOVERY  FROM  SYSTEMIC  VACCINIA  VIRUS  INFECTION 
By day 7, however, a clear difference between the two groups was apparent. Two 
of the three nonimmunosuppressed mice had no pathological lesions noted in 
any of the organs examined; the third mouse had only very rare areas of focal 
necrosis in the lungs and liver. All three mice receiving Cytoxan, on the other 
hand, had moderately severe bronchopneumonia and multiple areas of hepatic 
necrosis with many inflammatory cells. Two of three Cytoxan-treated mice also 
had areas of necrosis with inflammation in the myocardium at the base of the 
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FiG. 6.  Comparison of the effect of antibody and of immune lymphocytes on vaccinia virus 
infection in Cytoxan-treated C57/BL6 mice. 
heart and in the walls of the aortic and puhnonary arteries; these same two mice 
also had moderate polymorphonuclear cell infiltration of their spleens. None of 
the mice had pathological lesions in the kidneys. 
DISCUSSION 
The  present results indicate that  administration of  Cytoxan, in  amounts 
sufficient to suppress humoral and  cellular immunity, markedly potentiated 
primary systemic  vaccinia  virus infection in mice. Cytoxan-treated mice  did not 
form detectable neutralizing antibody to vacdnia virus, and had a prolonged 
and  more severe viremia than  nonimmunosuppressed control mice. Passive 
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infection,  at  a  time  when nonimmunosuppressed  mice had  similar  levels  of 
serum antibody, largely reversed the enhancing effect of Cytoxan on vaccinia 
virus infection. Passive transfer of 100 million immune spleen cells on day 3 
after infection was partially protective but was ineffective thereafter in revers- 
ing this effect of Cytoxan on vaccinia infection, and mice receiving these cells 
did appear to make some antibody. 
These results suggest that the formation of neutralizing antibody in the non- 
immunosuppressed mouse resulted in a termination of viremia, and that in this 
manner antibody played a critical role in limiting the primary vaccinia virus 
infection. The more severe viremia in immunosuppressed mice apparently re- 
sulted in more extensive dissemination of vaccinia virus to the target organs, 
particularly the lungs and liver. Our results do not exclude the possibility that 
antibody also played some direct role in recovery of infected target  organs. 
Because of a lack of an adequate, direct test for cellular immunity to vaccinia 
virus in the mouse, it is more difficult to reach a firm conclusion concerning the 
importance of this component of the immune response in the recovery process. 
However indirect  evidence indicates  that  Cytoxan  did  effectively suppress 
cellular immunity under the present experimental conditions. Cytoxan in the 
dose used has been shown to suppress cellular immunity in a variety of experi- 
mental systems (12). Cytoxan has been highly effective in preventing rejection 
of immunologically foreign lymphocytes by mice,  even when the donor and 
recipient differ across the H-2 locus (13). A  single dose of Cytoxan protected 
mice against  acute LCM disease  (9), which is thought to be a  cell-mediated 
immunopathological disease (10,  11). We have confirmed, under the conditions 
of the present experiments, the effect of Cytoxan on experimental infection with 
LCM virus. Perhaps most impressive is the ability of a single dose of Cytoxan to 
inhibit development of immunity to a bacteria, Listeria monocytogenes, in mice 
(14);  in  this  system Mackaness  and  his  colleagues have  demonstrated  that 
cellular immunity and not antibody is critical for recovery (15). These studies 
would suggest that Cytoxan probably had some effect on cellular immunity to 
vaccinia virus in our experiments. Whatever degree of suppression of cellular 
immunity to vaccinia virus was obtained with Cytoxan did not appear to be 
enough to explain the potentiation of the infection, since the effect of Cytoxan 
was almost entirely reversed by antibody administration. Additional support 
for the suggestion that cellular immunity may not play a decisive role in re- 
covery from primary vaccinia virus infection in mice comes from the observation 
in our laboratory that neonatally thymectomized mice, which have a very signif- 
icant defect in cellular immunity, recover normally from this infection (16). 
In recent years it has been demonstrated that an immune response is critical 
in recovery from a number of experimental, primary viral infections (4-7, 17- 
21). There are a number of possible mechanisms by which the immune response 
might  contribute to recovery during  a  primary virus infection. Neutralizing 
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and  thus  prevent  further  virus  dissemination;  alternately  antibody  could 
directly promote recovery of the infected target organs. Likewise cellular im- 
munity could play an  important role in  a  primary virus infection by either 
helping to control viremia or by assisting directly in the recovery process at the 
level of the target organ. Obviously these possible roles for the immune response 
are not mutually exclusive. 
Further clarification of specific roles for the components of the imnmne re- 
sponse comes from consideration of selected reports from the literature. A num- 
ber of studies have demonstrated that immunosuppression may potentiate a 
primary virus infection and that this potentiation may be accompanied by a 
suppression of neutralizing antibody formation and by a more severe vireinia 
(17-21).  In most of these studies it is likely that cellular immunity was  also 
suppressed to some extent, and specific replacement with antibody or immune 
cells has generally not been performed. However, in an excellent series of studies, 
Murphy  and  Glasgow  showed that  either X-irradiation  or a  combination of 
cyclophosphamide and thioguanine dramatically potentiated primary systemic 
encephalomyocarditis  (EMC)  virus  infection in  mice  and  that  formation of 
neutralizing antibody to EMC virus was suppressed by both of these methods of 
immunosuppression (22,  23). They also demonstrated that passive transfer of 
anti-EMC  antibody  could  protect  immunosuppressed  mice  if  administered 
early enough in the course of infection (23). The authors concluded that forma- 
tion of neutralizing antibody was critical during the viremic phase of primary 
EMC virus infection in mice. Cellular immunity was not measured and transfer 
of immune cells was not performed. These results with EMC virus are similar 
to our results with vaccinia virus. It would thus appear that in certain experi- 
mental virus infections neutralizing antibody plays a critical role by controlling 
viremia and preventing further virus dissemination. 
It is more difficult to find strong evidence to support a possible role for anti- 
body in directly promoting recovery of an infected target organ, and the studies 
already referred to  provide no  direct  information on  this  point.  In  general, 
passive transfer of even large amounts of antibody has not exerted a protective 
effect when the virus has been introduced directly into an organ such  as the 
brain (24). There are, however, at least two reports of instances in which trans- 
fer of antibody may have enhanced the recovery process (25,  26). In addition, 
immunosuppression has generally not potentiated primary virus infection when 
the virus is introduced directly into the target organ (4, 6, 23, 27). Exceptions to 
this general observation sometimes occur when experimental respiratory and 
intracranial viral infections are studied. Mice immunosuppressed with Cvtoxan 
and infected intranasally with Sendai virus develop higher titers of virus in the 
lung and have more extensive histologic  lesions than  nonimmunosuppressed 
control mice  (19). In  experiments in which intranasal  infection of mice  with 
Sendai  virus  was  potentiated  by immunosuppression,  serum  antibody  titers 
were found to be suppressed (19). This does not prove, however, that this sup- 
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tion. More recently Cytoxan-treated mice have been shown to be much more 
susceptible to i.c. infection with certain arboviruses (18). Antibody response to 
these arboviruses (18) was again suppressed in Cytoxan-treated mice, but it is 
quite likely that cellular immunity was also suppressed. These studies with arbo- 
viruses and Sendai virus do indicate that in certain experimental nonviremic 
infections an immune response is necessary for control of virus growth in the 
target organs. They do not, however, allow a definite statement as to which 
component of the immune response, antibody or cellular immunity, is critical in 
this process. The mechanisms by which antibody might promote target organ 
recovery could include prevention of virus adsorption to cells (28), lysis of virus 
(29), altered intracellular handling of virus-antibody complexes (30), and lysis of 
virus-infected cells (31). 
There is little evidence to support an important role for cellular immunity in 
controlling viremia in experimental virus infections. Neonatally thymectomized 
mice and  anti-thymocyte serum  (ATS)-treated mice have been shown  to be 
more susceptible to certain virus infections, including herpes simplex, vaccinia, 
and reovirus (5-7, 32). These two methods of immunosuppression have some- 
times been regarded as specific methods of suppression of cellular immunity; 
this is clearly not a valid conclusion, because they have also been demonstrated 
to suppress antibody formation to a variety of antigens (33, 34). In our labora- 
tory ATS-treated mice have also been demonstrated to be more susceptible to 
intravenous infection with vaccinia virus; this enhancement was accompanied 
by a suppression of antibody formation and a  more severe viremia. Further- 
more, replacement with physiologic amounts of antibody essentially completely 
reversed the  enhancement of this infection by ATS. Another study in ATS- 
treated monkeys demonstrated enhancement of monkeypox infection which was 
accompanied by a prolonged and more severe viremia (35). In this study, the 
appearance of neutralizing antibody was also delayed. In a recent careful  study 
by Blanden a single dose of ATS was sufficient to potentiate ectromelia infection 
in mice  (36).  Mice treated with ATS had highei  titers of virus in the blood, 
liver,  and spleen, but not in the footpad injection site,  well before antibody 
could be detected in  the  serum.  Transfer of immune  lymphocytes markedly 
reduced the titers of ectromelia in the spleen and liver; transfer of hyperimmune 
serum had a definite, but less dramatic effect (37). In this study suppression of 
cellular immunity appeared to be the major mechanism by which ATS poten- 
tiated ectromelia infection of the spleen and liver, but not in the footpad. The 
increase in virus titer occurred at the same time in the blood and the target 
organs, and so it is difficult to determine if the ATS acted by suppressing cell- 
mediated  immune  mechanisms  first  at  the  target  organ  level,  or  if  a 
cell-mediated  immune  mechanism  for  directly  controlling  viremia  was  also 
suppressed. Although not highly likely it is still possible that the ATS also acted 
to delay the first appearance of low levels of antibody which can effectively con- 
trol viremia since undiluted serum was not used for antibody assays. 
Cytoxan is a widely used immunosuppressive and antitumor agent in man; it 288  RECOVERY  FROM  SYSTEMIC  VACCINIA  VIRUS  INFECTION 
has recently been demonstrated to be effective in suppressing graft rejection in 
renal transplant patients  (38),  and it is quite possible that it will be used more 
extensively in the future in this group of patients. Fatal varicella infection has 
been reported in a child on Cytoxan therapy (39). Clearly such infections should 
be watched for carefully in patients receiving Cytoxan. 
SUMMARY 
Administration of Cytoxan in doses capable of inhibiting both humoral and 
cellular immunity markedly potentiated primary systemic vaccinia virus infec- 
tion in  mice.  Immunosuppressed mice did not form neutralizing  antibody to 
vaccinia virus and had a prolonged and more severe vilemia than nonilnmuno- 
suppressed control mice. Passive transfer of physiologic amounts of neutralizing 
antibody late in the course of infection, at a time when nonimmunosuppressed 
mice had similar levels of serum antibody, largely reversed the effect of Cytoxan 
on vaccinia virus infection.  Transfer  of 100 million immune spleen  cells  was 
much less effective than antibody in reversing the effect of Cytoxan on vaccinia 
virus infection, and mice receiving these cells did make some antibody. Serum 
interferon levels were not affected by Cytoxan. The results suggest an essential 
role for humoral antibody, but not for cellular immunity, in recovery from pri- 
mary vaccinia virus infection in the mouse. 
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